NCT04638192

Brief Summary

tACS has the potential to directly induce cortical alterations in the intrinsic neural oscillation at specific frequencies, and the brain could mirror the induced frequencies of the external source of oscillations from the stimulation. Hence, tACS with matching stimulation frequency could be an effective means of enhancing brain oscillatory activity to potentially induce synaptic plasticity for restoration of damaged brain functions. However from the existing studies of applying tACS over the M1 in healthy and diseased brains, there is a wide range of applied stimulation frequencies and varied neuromodulation effects on motor behavior or cortical excitability at different frequencies. In this proposal, subject-specific stimulation frequency and latency will be identified.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P50-P75 for not_applicable stroke

Timeline
Completed

Started Dec 2019

Typical duration for not_applicable stroke

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 16, 2019

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

November 17, 2020

Completed
3 days until next milestone

First Posted

Study publicly available on registry

November 20, 2020

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2021

Completed
Last Updated

November 20, 2020

Status Verified

November 1, 2020

Enrollment Period

2 years

First QC Date

November 17, 2020

Last Update Submit

November 17, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Magnetic resonance imaging

    Structural and functional MRI

    3-month after the 10th session training

Secondary Outcomes (3)

  • Action Research Arm Test (ARAT)

    3-month after the 10th session training

  • Fugl-Meyer Assessment (Upper Extremity)

    3-month after the 10th session training

  • Wolf Motor Function Test (WMFT)

    3-month after the 10th session training

Study Arms (3)

subject-specific tACS

EXPERIMENTAL

Constant current (1mA) will be applied for 20min at subject-specific stimulation frequency and latency

Device: tACS

standard tACS

EXPERIMENTAL

Constant current (1mA) will be applied for 20min at 20Hz with a fixed 25ms latency

Device: tACS

Sham tACS

SHAM COMPARATOR

The stimulator will be shut down after 30s of stimulation. The patients will feel the initial itching sensation at the beginning in order to evaluate the placebo effect

Device: tACS

Interventions

tACSDEVICE

A pair of 25 cm2 rubber electrodes enclosed in saline-soaked sponges and affixed to the head with rubber bands.

Sham tACSstandard tACSsubject-specific tACS

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Hemiparesis subsequent to first-ever unilateral stroke for more than 6 months;
  • MCP and PIP finger joints can be extended to 180° passively;
  • Sufficient cognition to follow the experimental instructions

You may not qualify if:

  • Severe hand spasticity or hand deformity;
  • History of alcohol or drug abuse or epilepsy;
  • Bilateral brain infarcts;
  • Severe cognitive deficits;
  • Comprehensive aphasia;
  • Contraindications to tACS and MRI

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Biomedical Engineering, The Chinese University of Hong Kong

Shatin, Hong Kong

RECRUITING

MeSH Terms

Conditions

Stroke

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Study Officials

  • Raymond Tong, PhD

    Department of Biomedical Engineering, The Chinese University of Hong Kong

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Raymond Tong, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Chairman and Professor

Study Record Dates

First Submitted

November 17, 2020

First Posted

November 20, 2020

Study Start

December 16, 2019

Primary Completion

December 1, 2021

Study Completion

December 1, 2021

Last Updated

November 20, 2020

Record last verified: 2020-11

Locations